BR112014009282A2 - ácido de meldrum, ácido barbitúrico e derivados de pirazol substituídos com hidroxilamina como doadores de hno - Google Patents

ácido de meldrum, ácido barbitúrico e derivados de pirazol substituídos com hidroxilamina como doadores de hno

Info

Publication number
BR112014009282A2
BR112014009282A2 BR112014009282A BR112014009282A BR112014009282A2 BR 112014009282 A2 BR112014009282 A2 BR 112014009282A2 BR 112014009282 A BR112014009282 A BR 112014009282A BR 112014009282 A BR112014009282 A BR 112014009282A BR 112014009282 A2 BR112014009282 A2 BR 112014009282A2
Authority
BR
Brazil
Prior art keywords
acid
compounds
disease
pyrazole derivatives
substituted pyrazole
Prior art date
Application number
BR112014009282A
Other languages
English (en)
Other versions
BR112014009282A8 (pt
BR112014009282B1 (pt
Inventor
a guthrie Daryl
p toscano John
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of BR112014009282A2 publication Critical patent/BR112014009282A2/pt
Publication of BR112014009282A8 publication Critical patent/BR112014009282A8/pt
Publication of BR112014009282B1 publication Critical patent/BR112014009282B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D231/08—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

resumo ácido de meldrum, ácido barbitúrico e derivados de pirazol substituídos com hidroxilamina como doadores de hno o objeto revelado proporciona certos compostos n-substituídos derivados de hidroxilamina, composições farmacêuticas e kits compreendendo estes compostos, e métodos de utilização de tais compostos ou composições farmacêuticas. em particular, o objeto revelado proporciona métodos de utilização de tais compostos ou de composições farmacêuticas para tratar, prevenir, ou retardar o aparecimento e/ou o desenvolvimento de uma doença ou condição. em algumas formas de realização, a doença ou condição é selecionada de doenças cardiovasculares, isquemia, lesão de reperfusão, doença cancerosa, a hipertensão pulmonar e condições que respondem a terapia de nitroxilo.
BR112014009282-6A 2011-10-17 2012-10-16 Composto, composição farmacêutica contendo-o e uso do mesmo BR112014009282B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161548036P 2011-10-17 2011-10-17
US61/548,036 2011-10-17
PCT/US2012/060425 WO2013059194A1 (en) 2011-10-17 2012-10-16 Meldrum 's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors

Publications (3)

Publication Number Publication Date
BR112014009282A2 true BR112014009282A2 (pt) 2017-06-13
BR112014009282A8 BR112014009282A8 (pt) 2020-04-22
BR112014009282B1 BR112014009282B1 (pt) 2021-12-14

Family

ID=47143299

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014009282-6A BR112014009282B1 (pt) 2011-10-17 2012-10-16 Composto, composição farmacêutica contendo-o e uso do mesmo

Country Status (13)

Country Link
US (3) US9181213B2 (pt)
EP (1) EP2776402B1 (pt)
JP (1) JP6177246B2 (pt)
KR (1) KR102061537B1 (pt)
CN (2) CN104053647B (pt)
AU (2) AU2013201929B2 (pt)
BR (1) BR112014009282B1 (pt)
CA (1) CA2852914C (pt)
HK (1) HK1200168A1 (pt)
IL (1) IL232101A (pt)
MX (1) MX363306B (pt)
SG (1) SG11201401587QA (pt)
WO (1) WO2013059194A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6177246B2 (ja) 2011-10-17 2017-08-09 ザ・ジョンズ・ホプキンス・ユニバーシティ ヒドロキシルアミンで置換された、ｈｎｏ供与体としてのメルドラム酸、バルビツール酸、及びピラゾロンの誘導体
JP6449171B2 (ja) 2013-01-18 2019-01-09 カルディオキシル ファーマシューティカルズ，インク． 治療指数の改善されたニトロキシル供与体
ES2734060T3 (es) 2014-01-17 2019-12-04 Cardioxyl Pharmaceuticals Inc Donadores de nitroxilo de N-hidroximetanosulfonamida
US9682938B2 (en) * 2014-05-27 2017-06-20 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
EP3148983A1 (en) 2014-05-27 2017-04-05 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives as nitroxyl donors
US9464061B2 (en) * 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
ES2871079T3 (es) * 2015-06-26 2021-10-28 Univ Johns Hopkins Acidos hidroxámicos N-sustituidos con grupos salientes a base de carbono como donantes eficaces de HNO y usos de los mismos
KR20180070672A (ko) 2015-10-19 2018-06-26 카르디옥실 파마슈티칼스 인코포레이티드 니트록실 공여자로서의 n-히드록실술폰아미드 유도체
US10723704B2 (en) 2015-10-19 2020-07-28 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
JP7194436B2 (ja) * 2016-07-28 2022-12-22 ザ ジョンズ ホプキンス ユニバーシティ Ｏ－置換ヒドロキサム酸
WO2018128999A1 (en) 2017-01-03 2018-07-12 Cardioxyl Pharmaceuticals, Inc. Method of administering nitroxyl donating compounds
IL277071B1 (en) 2018-03-08 2024-03-01 Incyte Corp Aminopyrizine diol compounds as PI3K–y inhibitors
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
US11912647B2 (en) 2020-05-22 2024-02-27 University Of Georgia Research Foundation, Inc. Diversity-oriented synthesis of N,N,O-trisubstituted hydroxylamines from alcohols and amines by N—O bond formation

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3751255A (en) 1972-03-24 1973-08-07 Eastman Kodak Co Photosensitive and thermosensitive element, composition and process
JPS567710A (en) 1979-06-28 1981-01-27 Sansho Seiyaku Kk Whitening cosmetic
US4539321A (en) 1981-10-26 1985-09-03 William H. Rorer, Inc. 5-Diaza-aryl-3-substituted pyridone compounds
EP0188040B1 (en) 1985-01-11 1991-08-14 Abbott Laboratories Limited Slow release solid preparation
US4663351A (en) 1985-08-23 1987-05-05 Berlex Laboratories, Inc. Dobutamine tri-isobutyric acid ester and the use thereof as a cardiotonic agent
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
BR9812982A (pt) 1997-10-24 2000-08-08 Shionogi & Co Agente anti-reumático
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6638534B1 (en) 1998-07-28 2003-10-28 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
GB0114223D0 (en) 2001-06-12 2001-08-01 Ici Plc Catalytic oxidation process
US20040038947A1 (en) 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
US6936639B2 (en) 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
WO2005061519A1 (en) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
EP1718621A4 (en) 2004-01-30 2009-08-19 Univ Johns Hopkins NITROXYL PREPARATION COMPOUNDS APPLICATION METHOD
US8168771B2 (en) 2005-01-31 2012-05-01 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
JP2008543947A (ja) 2005-06-23 2008-12-04 ジョンズ ホプキンス ユニバーシティ チオール感受性の正の変力物質
WO2007109175A1 (en) 2006-03-17 2007-09-27 Johns Hopkins University School Of Medicine N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
US7696373B2 (en) 2006-04-13 2010-04-13 Wake Forest University Health Sciences C-nitroso-derived nitroxyl donors
KR101905004B1 (ko) 2007-09-26 2018-10-08 존스 홉킨스 유니버시티 신규의 생리적으로 유용한 니트록실 도너로서 ｎ-히드록실술폰아미드 유도체
EP3067352A3 (en) 2008-05-07 2016-10-19 Cardioxyl Pharmaceuticals Inc. Novel nitroso compounds as nitroxyl donors and methods of use thereof
WO2011063339A1 (en) 2009-11-23 2011-05-26 Cardioxyl Pharmaceuticals, Inc. Nitroxyl donors for the treatment of pulmonary hypertension
US9018411B2 (en) * 2009-12-07 2015-04-28 Cardioxyl Pharmaceuticals, Inc. Bis-acylated hydroxylamine derivatives
AU2010328234B2 (en) 2009-12-07 2016-05-12 Cardioxyl Pharmaceuticals, Inc. N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivatives
JP6177246B2 (ja) 2011-10-17 2017-08-09 ザ・ジョンズ・ホプキンス・ユニバーシティ ヒドロキシルアミンで置換された、ｈｎｏ供与体としてのメルドラム酸、バルビツール酸、及びピラゾロンの誘導体
JP6449171B2 (ja) 2013-01-18 2019-01-09 カルディオキシル ファーマシューティカルズ，インク． 治療指数の改善されたニトロキシル供与体
US9682938B2 (en) 2014-05-27 2017-06-20 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
EP3148983A1 (en) 2014-05-27 2017-04-05 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives as nitroxyl donors

Also Published As

Publication number Publication date
KR20140107197A (ko) 2014-09-04
CN104053647A (zh) 2014-09-17
CN104053647B (zh) 2018-06-01
KR102061537B1 (ko) 2020-01-03
WO2013059194A1 (en) 2013-04-25
US9499511B2 (en) 2016-11-22
CA2852914C (en) 2019-11-26
US9862699B2 (en) 2018-01-09
US20160115148A1 (en) 2016-04-28
US20170050947A1 (en) 2017-02-23
JP6177246B2 (ja) 2017-08-09
IL232101A0 (en) 2014-05-28
AU2013201929B2 (en) 2015-07-23
CA2852914A1 (en) 2013-04-25
MX363306B (es) 2019-03-20
SG11201401587QA (en) 2014-07-30
BR112014009282A8 (pt) 2020-04-22
JP2015501308A (ja) 2015-01-15
US20140275134A1 (en) 2014-09-18
HK1200168A1 (en) 2015-07-31
US9181213B2 (en) 2015-11-10
AU2015246114A1 (en) 2015-11-12
BR112014009282B1 (pt) 2021-12-14
CN108409662B (zh) 2021-10-26
MX2014004596A (es) 2014-09-04
IL232101A (en) 2017-04-30
CN108409662A (zh) 2018-08-17
EP2776402B1 (en) 2017-07-26
EP2776402A1 (en) 2014-09-17
AU2013201929A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
BR112014009282A2 (pt) ácido de meldrum, ácido barbitúrico e derivados de pirazol substituídos com hidroxilamina como doadores de hno
AU2018236800B2 (en) DNA-PK inhibitors
BR112014026703A2 (pt) inibidores de dna-pk
BR112012030711A2 (pt) derivado de purinona
BR112017003312A2 (pt) compostos de indazol como inibidores de fgfr quinase, preparação e uso dos mesmos
BR112015003742A2 (pt) sistema de montagem de componente de descarga
BR112015021999A2 (pt) inibidores de indoleamina 2,3-dioxigenase (ido)
BR112015022545A2 (pt) compostos de pirazolo e os usos disso
BR112012007102A2 (pt) compostos policíclicos como antagonistas de receptores do ácido lisofosfatpidico
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
BR112014029139A8 (pt) compostos inibidores da atividade de catecol o-metiltransferase
CL2016001543A1 (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas.
BR112015005862A2 (pt) derivados de hidropirrolpirrol para uso como inibidores de ácido graxo sintase
IN2012DN05025A (pt)
WO2011138328A3 (en) Use of inhibitory molecules for the treatment of pulmonary hypertension
BR112014004319A2 (pt) compostos e composições como inibidores de c-kit cinase
BR112013031402A2 (pt) derivados de hidantoína como inibidores de kv3
CO6640327A2 (es) Compuestos de pirazol como inhibidores del receptor sigma
EA201491866A1 (ru) Способ обработки волос
BR112014019357A8 (pt) Derivados de tetra-hidro- quinazolinona como inibidores de tanc e parp
GT201700220A (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-lipoxigenasa (flap)
BR112016006388A2 (pt) inibidor seletivo da fosfatidilinositol 3-quinase gama
BR112018012590A2 (pt) formas cristalinas polimórficas do ácido obeticólico
BR112018013033A2 (pt) compostos de indolinonas e seu uso no tratamentod de doenças fibróticas
MX2015013936A (es) Compuestos de pirimidina condensada sustituida.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/10/2012, OBSERVADAS AS CONDICOES LEGAIS.